Articles

Boston, MA—The issues surrounding the cost of cancer care are large and looming in today’s healthcare landscape, but these problems are nothing compared to what is coming, according to Amitabh Chandra, PhD, Director of Health Policy Research, Harvard Kennedy School of Government, Cambridge, MA, who spoke at the War on Cancer forum organized by The Economist.

Copenhagen, Denmark—Two more PD-1 targeted drugs staked a claim to a role in treating advanced urothelial cancer, according to data from 2 studies that were reported at the 2016 European Society for Medical Oncology Congress.

Copenhagen, Denmark—Maintenance therapy with niraparib, an oral PARP inhibitor, significantly prolonged progression-free survival (PFS) in patients with recurrent, platinum-sensitive ovarian cancer regardless of their BRCA mutation status and homologous recombination deficiency (HRD) status.

Copenhagen, Denmark—The addition of the selective cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib to letrozole (Femara) significantly improved progression-free survival (PFS) in patients with hormone receptor (HR)-positive advanced breast cancer. Compared with letrozole alone, the combination of ribociclib plus letrozole improved PFS by 44%.

Boston, MA—Drug pricing in the pharmaceutical industry came under scrutiny at the recent War on Cancer forum organized by The Economist. An expert panel discussed the disassociation between the actual benefits of cancer drugs and their prices.